[
  {
    "ts": null,
    "headline": "AbbVie Inc. stock rises Tuesday, still underperforms market",
    "summary": "AbbVie Inc. stock rises Tuesday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=49e6db4112e986a2388942b0d3a03b16e2c486eb204ad8d284ab76b6b68bf237",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732034100,
      "headline": "AbbVie Inc. stock rises Tuesday, still underperforms market",
      "id": 131506169,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock rises Tuesday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=49e6db4112e986a2388942b0d3a03b16e2c486eb204ad8d284ab76b6b68bf237"
    }
  },
  {
    "ts": null,
    "headline": "Where Will AbbVie Be in 5 Years?",
    "summary": "Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine, and AbbVie (NYSE: ABBV) is no exception.  In the next five years, expect AbbVie to continue to compete in the disease areas that its pipeline and product mix are currently heavily focused around: immunology, neuroscience, and oncology.  It'll also likely continue to compete at a much smaller scale in aesthetics, eye medicines, and a grouping of other areas like infectious disease, but these efforts are ancillary at most.",
    "url": "https://finnhub.io/api/news?id=935fff8e0313291461923b0ebaa2c272c1e6269272bb16cb47fde57d31569d18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732028400,
      "headline": "Where Will AbbVie Be in 5 Years?",
      "id": 131484187,
      "image": "https://g.foolcdn.com/editorial/images/797891/two-investors-put-sticky-notes-on-glass-wall.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine, and AbbVie (NYSE: ABBV) is no exception.  In the next five years, expect AbbVie to continue to compete in the disease areas that its pipeline and product mix are currently heavily focused around: immunology, neuroscience, and oncology.  It'll also likely continue to compete at a much smaller scale in aesthetics, eye medicines, and a grouping of other areas like infectious disease, but these efforts are ancillary at most.",
      "url": "https://finnhub.io/api/news?id=935fff8e0313291461923b0ebaa2c272c1e6269272bb16cb47fde57d31569d18"
    }
  },
  {
    "ts": null,
    "headline": "ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap",
    "summary": "The FDA accepts Aldeyra's resubmitted NDA for topical ocular reproxalap to treat the signs and symptoms of dry eye disease. Stock rises.",
    "url": "https://finnhub.io/api/news?id=2c15ee1c9a4954b0df7d02c794b0a60a5cc1c72f0124cf59362bf082de178e80",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732028400,
      "headline": "ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap",
      "id": 131478542,
      "image": "https://media.zenfs.com/en/zacks.com/7813b4a575be05490cc210e943a2c6f1",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The FDA accepts Aldeyra's resubmitted NDA for topical ocular reproxalap to treat the signs and symptoms of dry eye disease. Stock rises.",
      "url": "https://finnhub.io/api/news?id=2c15ee1c9a4954b0df7d02c794b0a60a5cc1c72f0124cf59362bf082de178e80"
    }
  },
  {
    "ts": null,
    "headline": "How I Repurposed My Late Father's Trust Account",
    "summary": "I restructured my father's Trust for better diversification and risk reduction. See why I reduced Health Care and Consumer stocks and shifted to new sectors.",
    "url": "https://finnhub.io/api/news?id=15b16fcae92f6698a79d30b640741803fef606dc53bf6706d6ae2323f9f9d2f9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732019685,
      "headline": "How I Repurposed My Late Father's Trust Account",
      "id": 131478623,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/175431947/image_175431947.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "I restructured my father's Trust for better diversification and risk reduction. See why I reduced Health Care and Consumer stocks and shifted to new sectors.",
      "url": "https://finnhub.io/api/news?id=15b16fcae92f6698a79d30b640741803fef606dc53bf6706d6ae2323f9f9d2f9"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)",
    "summary": "Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield support a strong buy upgrade.",
    "url": "https://finnhub.io/api/news?id=46e4224bfbd8c3f561c918851d95bd0871c09f89b08895da85b7b639dfffea12",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732015683,
      "headline": "Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)",
      "id": 131474886,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/107429734/image_107429734.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield support a strong buy upgrade.",
      "url": "https://finnhub.io/api/news?id=46e4224bfbd8c3f561c918851d95bd0871c09f89b08895da85b7b639dfffea12"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Receives European Commission Approval of ELAHERE for the Treatment of Platinum-Resistant Ovarian Cancer",
    "summary": "NORTH CHICAGO - AbbVie today announced the European Commission granted marketing authorization for ELAHERE for the treatment of adult patients with folate receptor-alpha positive,...",
    "url": "https://finnhub.io/api/news?id=edb35c30346b2e139af556d712429a3bb3449f75424daf2914b773506f9bf4df",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732010061,
      "headline": "AbbVie Receives European Commission Approval of ELAHERE for the Treatment of Platinum-Resistant Ovarian Cancer",
      "id": 131471442,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "NORTH CHICAGO - AbbVie today announced the European Commission granted marketing authorization for ELAHERE for the treatment of adult patients with folate receptor-alpha positive,...",
      "url": "https://finnhub.io/api/news?id=edb35c30346b2e139af556d712429a3bb3449f75424daf2914b773506f9bf4df"
    }
  },
  {
    "ts": null,
    "headline": "RVPH: Year-End OLE Update",
    "summary": "By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT Operational and Financial Results On November 14 th , 2024, Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported third quarter 2024 financial and operational results and filed its Form 10-Q with the SEC. Reviva provided updates on its open label extension (OLE) trial and provided guidance for further milestones for",
    "url": "https://finnhub.io/api/news?id=57d5314401099bab75dc318f5ca33846e9438e1e119c46e2531a945ba466a1ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732008300,
      "headline": "RVPH: Year-End OLE Update",
      "id": 131479239,
      "image": "https://s.yimg.com/ny/api/res/1.2/QkLqWm6frJ6FEX67vKRm.w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0xMTI4/https://media.zenfs.com/en/scr.zacks.com/416b7ca43f6341d3f351f7657566bc92",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT Operational and Financial Results On November 14 th , 2024, Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported third quarter 2024 financial and operational results and filed its Form 10-Q with the SEC. Reviva provided updates on its open label extension (OLE) trial and provided guidance for further milestones for",
      "url": "https://finnhub.io/api/news?id=57d5314401099bab75dc318f5ca33846e9438e1e119c46e2531a945ba466a1ee"
    }
  },
  {
    "ts": null,
    "headline": "IXJ: Healthcare Sector Dashboard For November",
    "summary": "November dashboard shows the healthcare sector is overvalued by 18% relative to 11-yr averages; pharma/biotech and healthcare equipment, the most overpriced.",
    "url": "https://finnhub.io/api/news?id=17b2ae374f72b898be1e13a220d648b578b5b9ae1db05e9f4365ec93e3d05504",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732007700,
      "headline": "IXJ: Healthcare Sector Dashboard For November",
      "id": 131471159,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/688000635/image_688000635.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "November dashboard shows the healthcare sector is overvalued by 18% relative to 11-yr averages; pharma/biotech and healthcare equipment, the most overpriced.",
      "url": "https://finnhub.io/api/news?id=17b2ae374f72b898be1e13a220d648b578b5b9ae1db05e9f4365ec93e3d05504"
    }
  },
  {
    "ts": null,
    "headline": "What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine",
    "summary": "AbbVie’s head of R&D cures has lofty ambitions to end diseases like HIV through a community of researchers that work as one.",
    "url": "https://finnhub.io/api/news?id=c560f627ada3a4f07e338ad01f4d0d91fa6bb248e7ccc636faac3add03118f51",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732003200,
      "headline": "What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine",
      "id": 131484195,
      "image": "https://imgproxy.divecdn.com/_lD90YGNRoLbLuFAuoOTNZcNz29vt0PO4lnydx5WuQ0/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9Kb2NoZW4taGVhZHNob3QuanBn.webp",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie’s head of R&D cures has lofty ambitions to end diseases like HIV through a community of researchers that work as one.",
      "url": "https://finnhub.io/api/news?id=c560f627ada3a4f07e338ad01f4d0d91fa6bb248e7ccc636faac3add03118f51"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Select Health Care Portfolio Q3 2024 Fund Review",
    "summary": "For Q3 2024, the Fidelity Select Health Care Portfolio fund gained 9.48%, outperforming the MSCI sector index. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=f19c540ed18a1c2f912d6ff2c1c5be2a7f351bca6a9d716c8a57b31d84916382",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731993000,
      "headline": "Fidelity Select Health Care Portfolio Q3 2024 Fund Review",
      "id": 131467028,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1849023174/image_1849023174.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "For Q3 2024, the Fidelity Select Health Care Portfolio fund gained 9.48%, outperforming the MSCI sector index. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=f19c540ed18a1c2f912d6ff2c1c5be2a7f351bca6a9d716c8a57b31d84916382"
    }
  }
]